Journal of Viral Hepatitis最新文献

Cost-Effectiveness of Universal Screen-and-Treat Strategies for Reducing Morbidity and Mortality of Chronic Hepatitis B in a High-Endemicity City

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-04-01 DOI: 10.1111/jvh.70027

Ngai Sze Wong, Denise Pui-Chung Chan, Grace Lai-Hung Wong, Shui Shan Lee

{"title":"Cost-Effectiveness of Universal Screen-and-Treat Strategies for Reducing Morbidity and Mortality of Chronic Hepatitis B in a High-Endemicity City","authors":"Ngai Sze Wong, Denise Pui-Chung Chan, Grace Lai-Hung Wong, Shui Shan Lee","doi":"10.1111/jvh.70027","DOIUrl":"https://doi.org/10.1111/jvh.70027","url":null,"abstract":"In the setting of high hepatitis B virus (HBV) endemicity, we studied the cost-effectiveness of universal HBV screen-and-treat strategies for averting HBV-related morbidity and mortality in Hong Kong, where diagnosis and treatment coverages are low. An age–sex-specific compartmental model for 2000–2040 was developed, with the incorporation of population-based screening strategies targeting different age groups. With a one-time HBV screening programme in 2025–2029, 3.6%–8.9% of HBV-related deaths could be averted. We evaluated the cost-effectiveness of the screening strategies with primary-care-based management in different scenarios with components of annual drug cost levels, screening programme duration, starting year and targeted age groups. Incremental cost-effectiveness ratio (ICER) was calculated, with the willingness-to-pay (WTP) threshold set at USD100,000/quality-adjusted life years (QALY). At the standard drug cost level, only the screening strategy targeting the 40–49 years old is cost-saving. When drug cost decreases to a low level, the strategy targeting the 35–49 years old (ICER USD97,042/QALY gained) is likely to be cost-effective and screening 35–59 years old is marginally cost-effective. In probabilistic sensitivity analysis, screening 40–49 years old (50%) and 35–59 years old (42%) have a half–half probability of being the most cost-effective at USD100,000/QALY WTP threshold, but increased to 93% for screening 35–59 years old at USD150,000/QALY threshold. From scenario analysis, deferred initiation of screening and unlimited programme duration would increase the ICER. Universal HBV screening targeting individuals aged 35–59 years or 40–49 years in the general population, with an earlier start and limited duration of the programme, is likely to be cost-effective.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 5","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143749687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global Burden and Trends of Acute Hepatitis C From 1990 to 2021: An Analysis Based on the 2021 Global Burden of Disease Study

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-03-27 DOI: 10.1111/jvh.70026

Xinwei Wang, Xipeng Yan, Baoren He, Bin Li, Linbin Huang, Jinlian Li, Rongji Lai, Mingshuang Lai, He Xie, Limin Chen

{"title":"Global Burden and Trends of Acute Hepatitis C From 1990 to 2021: An Analysis Based on the 2021 Global Burden of Disease Study","authors":"Xinwei Wang, Xipeng Yan, Baoren He, Bin Li, Linbin Huang, Jinlian Li, Rongji Lai, Mingshuang Lai, He Xie, Limin Chen","doi":"10.1111/jvh.70026","DOIUrl":"https://doi.org/10.1111/jvh.70026","url":null,"abstract":"<div>\u0000 \u0000 Acute hepatitis C (AHC) represents a considerable challenge to global public health, although direct-acting antiviral (DAA) therapy has substantially improved therapeutic outcomes for hepatitis C virus infection. Data were exclusively obtained from the 2021 Global Burden of Disease (GBD) study, which examined trends in the burden of AHC in terms of incidence, mortality and disability-adjusted life years (DALYs) across 204 countries and territories globally from 2009 to 2021. In 2021, there were 7,009,910.02 incident cases, 5474.37 deaths and 266,087.98 DALYs due to AHC. Between 1990 and 2021, the number of incident cases increased by 24.61%, whereas mortality and DALYs cases decreased by 45.66% and 46.57%, respectively. The age-standardised incidence rate (ASIR), age-standardised mortality rate (ASMR) and age-standardised DALYs rate (ASDR) exhibited a declining trend. In 2021, the highest ASIRs of AHC were observed in Central Sub-Saharan Africa and Central Asia. At a national level, Mongolia and Egypt reported the highest ASIRs in 2021. The ASIR of AHC was similar in males and females, while females had higher ASMR and ASDR than males. The highest ASIR was observed in children under 5 years of age. Additionally, a negative association was found between the ASIR, ASMR, ASDR of AHC and sociodemographic index values at the regional and national levels. Our findings underscore the persistent severity of the global burden of AHC; effective and targeted strategies are needed to reduce the overall burden.\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 5","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sensitivity Analysis of Hepatitis B and C Mortality in England Using Data Linkage: Meeting the WHO Elimination Threshold for Mortality

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-03-26 DOI: 10.1111/jvh.70016

Annabel A. Powell, Annastella Costella, Rachel Roche, David Leeman, Ashley Brown, Beatrice Emmanouil, Mark Gillyon-Powell, Ross Harris, Holly D. Mitchell, Ruth Simmons, Monica Desai

{"title":"Sensitivity Analysis of Hepatitis B and C Mortality in England Using Data Linkage: Meeting the WHO Elimination Threshold for Mortality","authors":"Annabel A. Powell, Annastella Costella, Rachel Roche, David Leeman, Ashley Brown, Beatrice Emmanouil, Mark Gillyon-Powell, Ross Harris, Holly D. Mitchell, Ruth Simmons, Monica Desai","doi":"10.1111/jvh.70016","DOIUrl":"https://doi.org/10.1111/jvh.70016","url":null,"abstract":"The United Kingdom, along with many other countries, is working towards eliminating viral hepatitis as a public health threat by 2030, with a combined mortality target of less than or equal to six deaths per 100,000 population. The current methodology of reporting uses death registrations alone, which has been estimated to underestimate mortality rates by up to 60% for hepatitis C (HCV)-related liver disease. We aim to conduct a sensitivity analysis using data linkage of death certificates, hepatitis B (HBV) and HCV diagnoses and admissions for end-stage liver disease (ESLD) and/or hepatocellular carcinoma (HCC) to estimate mortality rates, assess progress towards elimination and evaluate underreporting. Between 2000 and 2023, 7967 deaths were reported due to HBV- and/or HCV-associated ESLD and/or HCC. Using data linkage of all three datasets, this increased to 11,487, with underreporting estimated to be 37% overall. The upper bound combined mortality rate was estimated to be 1.3 deaths per 100,000 population at its peak in 2015, therefore surpassing the WHO target for all years evaluated. From 2015 to 2023, both HCV-associated ESLD and/or HCC mortality decreased (1.12 to 0.88 deaths per 100,000 population), however, there was a slight increase for HBV-associated ESLD and/or HCC deaths during the same time frame (0.3 to 0.35). A higher proportion of HBV-related deaths were in males (p < 0.05) who died outside London (p < 0.05) and a lower proportion were White (p < 0.05) when compared to HCV-related deaths. While England has met the WHO impact targets, it is important we continue to drive reductions in mortality.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of Hepatitis C Among Migrants: A Systematic Review and Meta-Analysis

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-03-21 DOI: 10.1111/jvh.70025

Jiajun Sun, Matthew Kelly, Tsheten Tsheten, Davoud Pourmarzi

{"title":"Prevalence of Hepatitis C Among Migrants: A Systematic Review and Meta-Analysis","authors":"Jiajun Sun, Matthew Kelly, Tsheten Tsheten, Davoud Pourmarzi","doi":"10.1111/jvh.70025","DOIUrl":"10.1111/jvh.70025","url":null,"abstract":"The World Health Organisation has targeted the Hepatitis C virus (HCV) to be eliminated as a public health threat by 2030. Equitable access to HCV testing and treatment services is important in achieving this goal. Migrants often face barriers to accessing health services, and understanding HCV prevalence among this population can support planning for elimination. This systematic review aimed to estimate HCV prevalence among migrants residing in high-income countries with low/intermediate HCV prevalence. Scopus, PubMed, PsycINFO and Cochrane Library were searched for peer-reviewed articles published in English between 2015 and 2024. The studies' quality was assessed using The Joanna Briggs Institute (JBI) Critical Appraisal Tools. A proportional meta-analysis was used to estimate HCV prevalence. Thirty-seven studies were included in this review. Seventeen studies included both people < 18 and ≥ 18 years old, 16 studies only included people ≥ 18 years old, and three studies included people aged 18 and younger. The pooled prevalence of HCV antibody (anti-HCV) and RNA (HCV-RNA) were 1.5% (95% CI, 1.1%–2.0%) and 0.6% (95% CI, 0.4%–0.9%), respectively. The prevalence of anti-HCV was higher among males (1.9%) than females (0.6%). Among refugees and asylum seekers, the prevalence of anti-HCV and HCV-RNA were 1.4% and 0.7%, respectively. The prevalence of HCV among migrants is comparable with that among the general population of the destination countries. Given the barriers migrants, especially refugees and asylum seekers, face in accessing health services, their access to HCV information, testing and treatment should be facilitated.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and Validation of a High-Sensitivity Droplet Digital PCR Assay for Serum Hepatitis B Virus DNA Detection

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-03-15 DOI: 10.1111/jvh.70023

Rex Wan-Hin Hui, Danny Ka-Ho Wong, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen

{"title":"Development and Validation of a High-Sensitivity Droplet Digital PCR Assay for Serum Hepatitis B Virus DNA Detection","authors":"Rex Wan-Hin Hui, Danny Ka-Ho Wong, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen","doi":"10.1111/jvh.70023","DOIUrl":"https://doi.org/10.1111/jvh.70023","url":null,"abstract":"Real-time polymerase chain reaction (PCR) is the current standard for serum HBV DNA measurement. However, conventional real-time PCR assays have technical limitations, and are not sensitive enough to detect low-level residual viremia in chronic hepatitis B (CHB) patients. We developed and validated a droplet digital PCR (ddPCR) assay for high-sensitivity detection of serum HBV DNA. A ddPCR assay was developed on the QX200 ddPCR System (Bio-Rad) for detection of serum HBV DNA in 200 μL of serum. The primers and probe were designed to target a highly-conserved region in the HBV X gene. The AcroMetrix HBV Panel (Thermo Fisher Scientific) and CHB patient samples were used for validation experiments to determine the assay sensitivity, specificity, linearity, intra-run variability, and inter-run variability. The ddPCR assay demonstrated lower limit of detection of 1.6 IU/mL and lower limit of quantification of 9.4 IU/mL for serum HBV DNA in probit regression. The assay also achieved excellent specificity (96.2%), linearity (R = 0.994, R2= 0.988, p < 0.001), intra-run variability (mean coefficient of variation [CV]: 0.69%, average intra-run difference: 0.026 log IU/mL), and inter-run variability (mean coefficient of variation [CV]: 4.54%, average inter-run difference: 0.18 log IU/mL). To conclude, we developed a robust ddPCR assay that achieved higher detection sensitivity with lower serum input volume than conventional real-time PCR assays. Our assay may be utilised for measuring residual viremia after nucleos(t)ide analogue therapy or for monitoring patients on novel HBV antivirals.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Different Antiviral Treatments on Liver Inflammation and Fibrosis in Patients With Chronic Hepatitis B

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-03-15 DOI: 10.1111/jvh.70019

Huiqing Liang, Xiaoting Zheng, Yaoyu Liu, Qianguo Mao, Chuncheng Wu, Li Lin, Zhizhen Huang, Yue Chen, Manying Zhang, Luyun Zhang, Jia Min, Min Hu, Huiying Luo, Shaodong Chen, Xiaohong Gu

{"title":"Effects of Different Antiviral Treatments on Liver Inflammation and Fibrosis in Patients With Chronic Hepatitis B","authors":"Huiqing Liang, Xiaoting Zheng, Yaoyu Liu, Qianguo Mao, Chuncheng Wu, Li Lin, Zhizhen Huang, Yue Chen, Manying Zhang, Luyun Zhang, Jia Min, Min Hu, Huiying Luo, Shaodong Chen, Xiaohong Gu","doi":"10.1111/jvh.70019","DOIUrl":"https://doi.org/10.1111/jvh.70019","url":null,"abstract":"<div>\u0000 \u0000 Oral nucleotide analogues (NAs) and peginterferon-α injections are commonly used for the treatment of patients with chronic hepatitis B (CHB). This study aims to evaluate the effects of different antiviral therapies on the degree of liver inflammation and fibrosis in CHB patients. This was a retrospective cohort study. A total of 101 CHB patients were admitted to the Liver Center of Xiamen Hospital of Traditional Chinese Medicine from 2017 to 2021 and were divided into three groups for different antiviral treatments: NAs therapy group (n = 36), peginterferon-α therapy group (n = 38) and nonantiviral therapy group (n = 27). The differences in degrees of liver inflammation and liver fibrosis between two histopathologic biopsies before and after treatment were analysed and compared to evaluate the efficacy of different treatments. The degrees of liver inflammation and liver fibrosis were improved after NAs or peginterferon-α therapy. In terms of improving the degree of liver inflammation, peginterferon-α therapy (74%) and NAs therapy (44%) were better than nonantiviral therapy (11%, p < 0.05), although no significant difference was shown between peginterferon-α therapy and NAs therapy (p = 0.974). For liver fibrosis improvement, peginterferon-α therapy showed significantly better efficacy than NAs therapy (68% vs. 33%, p = 0.044), while NAs therapy was better than nonantiviral therapy (33% vs. 11%, p = 0.028). Peginterferon-α and NAs can significantly improve the degree of liver inflammation and liver fibrosis in CHB patients. Peginterferon-α is superior to NAs in delaying and reversing liver fibrosis. This study provides a new basis for peginterferon-α therapy to prevent progression of fibrosis in CHB patients.\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-03-15 DOI: 10.1111/jvh.70022

Svenja Hardtke, Cihan Yurdaydin, Florin A. Caruntu, Manuela G. Curescu, Kendal Yalcin, Ulus S. Akarca, Selim Gürel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George V. Papatheodoridis, Kerstin Port, Michael P. Manns, Markus Cornberg, Julia Kahlhöfer, Heiner Wedemeyer

{"title":"Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection","authors":"Svenja Hardtke, Cihan Yurdaydin, Florin A. Caruntu, Manuela G. Curescu, Kendal Yalcin, Ulus S. Akarca, Selim Gürel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George V. Papatheodoridis, Kerstin Port, Michael P. Manns, Markus Cornberg, Julia Kahlhöfer, Heiner Wedemeyer","doi":"10.1111/jvh.70022","DOIUrl":"https://doi.org/10.1111/jvh.70022","url":null,"abstract":"We analysed the frequency, severity and impact of hepatitis flares in a large Phase 2 study investigating pegylated interferon-alfa-2a (PEG-IFNa) for the treatment of hepatitis D. In the HIDIT-II study, 120 patients were treated for 96 weeks with PEG-IFNa (180 μg weekly) in combination with tenofovir disoproxil fumarate (TDF, 300 mg once daily) or placebo. Hepatitis flares were defined as ALT increases above 10 times the upper limit of normal or increases of more than 2.5-fold above baseline or nadir values. ALT flares occurred in 28 patients (23%) during treatment (< 96) and in 14 patients post-treatment until follow-up Week 24. There were no differences in the flare frequency between the two treatment arms (12 PEG-IFNa + placebo vs. 16 PEG-IFNa + TDF). The frequency of ALT increases did not differ between cirrhotic and noncirrhotic patients. None of the patients with cirrhosis experienced liver decompensation during or after a flare. Fifty-four per cent of the patients with ALT flare experienced a decrease in HDV RNA (> 1 log10 cop/ml) during subsequent study visits. Mean ALT levels early during treatment were higher in patients with HBsAg loss at follow-up Week 24. More than a third of hepatitis D patients undergoing PEG-IFNa therapy may experience ALT flares during or after treatment. ALT flares in this study posed no obvious safety risk to patients and should not lead to premature withdrawal from treatment. If ALT flares may be beneficial in single patients requires further investigation.Clinical Trial Registration: NCT00932971, EudraCT 2008–005560-13.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of HBV Infection in Couples on In Vitro Fertilisation-Embryo Transfer Outcomes and Clinical Characteristics of Newborns: A Retrospective Study Based on 3900 Infertile Couples

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-03-11 DOI: 10.1111/jvh.70015

Kaiwen Xue, Leji Wen, Xiaolei Ji, Xiaoyue Yan, Jiaqi Wen, Youzhu Li, Lei Zhang

{"title":"Impact of HBV Infection in Couples on In Vitro Fertilisation-Embryo Transfer Outcomes and Clinical Characteristics of Newborns: A Retrospective Study Based on 3900 Infertile Couples","authors":"Kaiwen Xue, Leji Wen, Xiaolei Ji, Xiaoyue Yan, Jiaqi Wen, Youzhu Li, Lei Zhang","doi":"10.1111/jvh.70015","DOIUrl":"https://doi.org/10.1111/jvh.70015","url":null,"abstract":"<div>\u0000 \u0000 To investigate the effects of chronic HBV infection on the outcome of in vitro fertilisation-embryo transfer and clinical characteristics of newborns, as well as the factors influencing different outcomes of in vitro fertilisation-embryo transfer (IVF-ET). In this study, a total of 3900 couples undergoing IVF-ET were collected and divided into four groups according to the different HBsAg carrier status of each couple, comparing the general demographic data and clinical characteristics between the four groups, analysing the differences in IVF-ET outcomes between the groups, and using multifactorial analysis of factors influencing their IVF-ET outcomes. The results showed that no significant differences (p > 0.05) were found in IVF-ET outcomes among the four groups, but multifactorial logistic regression showed that male and female age, low literacy level of men, total number of eggs acquired, LH value and P value on HCG day may affect the success rate of different IVF-ET outcomes (embryo outcome, pregnancy outcome and perinatal outcome) to different degrees. We also analysed the clinical data of 952 newborns and there were no statistically significant differences (p > 0.05) in variables including sex distribution, length, weight, health status and Apgar score. Therefore, our study suggests that neither uniparental infection nor biparental HBV infection may affect the outcome of IVF-ET or the clinical characteristics of the newborns, but the outcome of IVF-ET is affected by different factors.\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-03-07 DOI: 10.1111/jvh.70021

Jun Inoue, Shinichiro Minami, Kazumichi Abe, Mami Kida, Hiroaki Haga, Chikara Iino, Hiroshi Numao, Hidekatsu Kuroda, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Takehiro Akahane, Tomoo Kobayashi, Hiromasa Ohira, Yoshiyuki Ueno, Atsushi Masamune

{"title":"Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues","authors":"Jun Inoue, Shinichiro Minami, Kazumichi Abe, Mami Kida, Hiroaki Haga, Chikara Iino, Hiroshi Numao, Hidekatsu Kuroda, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Takehiro Akahane, Tomoo Kobayashi, Hiromasa Ohira, Yoshiyuki Ueno, Atsushi Masamune","doi":"10.1111/jvh.70021","DOIUrl":"https://doi.org/10.1111/jvh.70021","url":null,"abstract":"Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC) worldwide. Nucleos(t)ide analogues (NAs) are widely used in chronically HBV-infected patients, but the risk of HCC still remains in NA-treated patients. In this study, we aimed to validate the HCC risk scores for HBV-infected patients treated with nucleos(t)ide analogues (NAs). Among a total of 360 chronically HBV-infected patients who were treated with NAs, 253 patients without a history of HCC were used to validate the PAGE-B, mPAGE-B, PAGED-B, APA-B, and aMAP scores, as well as a recently developed score, the FAL-1 score, which consists of the FIB-4 index and ALT at 1 year of NA. In this cohort, the cumulative incidence of HCC at 5, 10, and 15 years was 2.9%, 7.8% and 11.0%, respectively. Most scores significantly stratified the HCC incidence and, for the FAL-1 score, the cumulative incidence of HCC at 10 years was 0%, 11.3% and 17.2% for the score-0 (n = 91), score-1 (n = 129) and score-2 (n = 30) groups, respectively. Compared with the other scores, the FAL-1 score was shown to efficiently identify patients at very low risk of HCC. An analysis using both this validation and the previously reported derivation cohorts demonstrated the utility in patients with either HBV genotype B or C. In conclusion, the utility of the FAL-1 score was reproduced in this validation study as well as other scores. In particular, the FAL-1 score may be useful to efficiently identify patients with a low risk of HCC.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic Screening for Hepatitis B, C, and HIV and Linkage to Care in Patients With Mental Health Disorders Admitted to the Emergency Department

IF 2.5 3区医学

Journal of Viral Hepatitis Pub Date : 2025-03-07 DOI: 10.1111/jvh.70018

Prabakar Vaittinada Ayar, Jamal Abdelkader, Matthieu Gay, Raphaël Allali, Cécilia De Freitas, Béatrice Monnier, Enrique Casalino, Nathalie Boyer, Tarik Asselah

{"title":"Systematic Screening for Hepatitis B, C, and HIV and Linkage to Care in Patients With Mental Health Disorders Admitted to the Emergency Department","authors":"Prabakar Vaittinada Ayar, Jamal Abdelkader, Matthieu Gay, Raphaël Allali, Cécilia De Freitas, Béatrice Monnier, Enrique Casalino, Nathalie Boyer, Tarik Asselah","doi":"10.1111/jvh.70018","DOIUrl":"https://doi.org/10.1111/jvh.70018","url":null,"abstract":"<div>\u0000 \u0000 People with mental health disorders have a significant lack of physical health care. They also have higher rates of medical co-morbidity. The aim of this study was to assess the feasibility and the linkage to care of systematic screening for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in patients admitted for an acute psychiatric event at the emergency department (ED). This was an observational prospective cohort study for 1 year. Systematic screening was performed for HBV, HCV and HIV for all adult patients presenting to the ED for acute psychiatric reasons. This was a collaborative work between 3 departments (emergency, hepatology and psychiatry). A total of 584 patients were included. The median age was 42 years (range 29–56) with 304 (52%) men. Among all study patients, 50% were hospitalised in the psychiatry ward, and 38 (7%) had a positive serological screening, including 9 (2%), 19 (3%) and 12 (2%), respectively, for HBV, HCV and HIV. Among 19 patients with HCV, 12 had negative HCV RNA, 2 were treated and cured, and 5 were lost to follow-up. This study demonstrated the feasibility of HBV, HCV and HIV screening and linkage to care programmes in people with mental health disorders in the ED. The medical importance for this at-risk population confirms the significant benefit of continuing this screening in hospitals or as outpatients.\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0